Search

Pulmonary micro-embolism in a healthy donor following G-CSF administration for mobilization of hemopoietic progenitor cells

Healthy donors (HDs) who were mobilized using lenograstim (LENO) and who were undergoing peripheral haematopoietic progenitor cell collection with apheresis (HPC-A) were enrolled in a surveillance protocol. In all, 184 HDs have been assessed with a median follow-up of 62 months (range 2-155). HDs received LENO at a median dose of 10 microg/kg (range 5-15). Bone pain was reported as the most frequent short-term adverse event (71.2%). Other commonly observed short-term symptoms included fatigue (19.0%), fever (5.4%), headache (27.7%), nausea (12.0%) and insomnia (22.3%). Spleen size increased in 4.3% of the donors. No vascular disorders or cardiac disease occurred. Long-term follow-up included monitoring of adverse events, neoplastic disease or other pathologies. Transit ischaemic attack occurred in one donor (39 months post-donation). One autoimmune event was reported at 28 months post-recombinant human granulocyte (rhG)-CSF (ankylosing spondylitis); one donor with a history of chronic obstructive pulmonary disease developed secondary polyglobulia (50 months post-rhG-CSF). One donor was diagnosed with lung cancer at 19 months post-donation. No haematological disease was observed. In conclusion, the short-term safety appears to be verified, whereas, although the study identified no increased risks of malignancy among HDs who received rhG-CSF, long-term safety requires more complete data sets, especially a longer follow-up and a larger number of HDs.

e18577 Background: After high-dose chemotherapy with autologous stem-cell support, long hospital stays in the aplastic phase are expensive, lead to increased risk of hospital infections and to incr...

19533 Healthy allogeneic donors, who were mobilized with G-CSF and underwent hemopoietic peripheral cells (HPC-A) collection at our Institution, were enrolled in a short- and long-term surveillance...

7103 Purpose: To decrease red blood cell (RBC) transfusion requirements during a tandem high-dose melphalan (HDM) for multiple myeloma (MM) patients (PTS), we conducted a pilot study to assess the effect of high-dose of recombinant human erythropoietin (rHuEpo) started during chemotherapy before the first HDM and autologous peripheral blood stem-cell transplantation (APBSCT). Patients and Methods: After induction chemotherapy with VAD, 14 consecutive PTS with MM, stage III, median age 58 years (range 42–62), were mobilized with cyclophosphamide (3–4 g/m2) to collect peripheral blood stem cells (PBSC) and entered a study consisting of two HDM (200 mg/m2) with APBSCT. Enrolled patients received rHuEpo (40,000 U subcutaneously one time/week) as soon as their hemoglobin (Hb) level fell No significant financial relationships to disclose.

This contribution describes the way in which the ECAD facilities have been exploited in the development of an undergraduate curriculum for the teaching of IC design in an Electronic Systems B. Eng. degree scheme. The programme of course and laboratory work culminates in a final year core course in Microelectronic Circuit Technology and Design together with a specialist option in VLSI Systems Design which includes chip fabrication activities.

The design of a class of canonical multi-loop feedback RC-active filters that has received considerable attention in the literature is considered. The favourable features of the structure aro reviewed, but it is shown that practical considerations preclude the realization, theoretically possible, of high-order structures. The present contribution examines the possibility of medium-order cascade realizations of higher-order filters and it is established that practical filters can be obtained by this means. General design guidelines are presented to assist in the optimum partitioning of filters of this class.